Home > Insider Trading > Filing (0001079973-25-000525)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1799191	Oncology Institute Inc.	TOI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1321250	L Mark Pacala	C/O The Oncology Institute Inc. 18000 Studebaker Rd, Suite 800 Cerritos CA 90703		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-03-26	90,562	$1.04	224,971	No	4	P	Indirect	By LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By LLC

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Warrant	Acquisiton	2025-03-26	42,281	$0.13	42,281	$1.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
42,281	2025-03-26	2030-03-26	No	4	P	Indirect

Footnotes

Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250.
Securities were purchased by Pacala Enterprises, LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein.
The holder may not exercise any portion of a Common Warrant to the extent that the holder would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Securities Exchange Act of 1934, as amended.